Hologic Acquires Acessa To Add ProVu Fibroid Treatment
Hologic has agreed to pay $80m in cash, plus contingent payments for Acessa, a privately held developer of minimally invasive treatments for uterine fibroids.
Hologic has agreed to pay $80m in cash, plus contingent payments for Acessa, a privately held developer of minimally invasive treatments for uterine fibroids.